Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Cash & Equivalents (2022 - 2025)

Ascentage Pharma Group International posted quarterly Cash & Equivalents of $168.6 million for Q4 2025, up 35.6% year-on-year from $124.3 million in Q4 2024, and up 35.6% on a QoQ basis from $124.3 million in Q4 2024.

Ascentage Pharma Group International (AAPG) has 4 years of Cash & Equivalents data on file, last reported at $168.6 million in Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 35.6% year-over-year to $168.6 million; the trailing twelve-month figure through Dec 2025 stood at $168.6 million (up 35.6% YoY), and the FY2025 full-year result was $171.0 million, up 33.89% from the prior year.
  • Cash & Equivalents for Q4 2025 stood at $168.6 million, up from $124.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $189.2 million in Q4 2022 and bottomed at $124.3 million in Q4 2024.
  • The 4-year median for Cash & Equivalents is $156.4 million (2025), against an average of $156.6 million.
  • The widest annual swing landed in 2023, when Cash & Equivalents slipped 23.8%; it then soared 35.6% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $189.2 million in 2022, then dropped by 23.8% to $144.2 million in 2023, then decreased by 13.76% to $124.3 million in 2024, then jumped by 35.6% to $168.6 million in 2025.
  • The last three Cash & Equivalents figures came in at $168.6 million (Q4 2025), $124.3 million (Q4 2024), and $144.2 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - 1.91 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - 32.30 Mn
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn 901.90 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - 61.46 Mn
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - 2.77 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 5.49 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 2.96 Bn
8 Evaxion A 65.44 Bn 65.42 Bn - 18.44 Mn
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 1.71 Bn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn - 168.60 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 168.60 Mn
Dec 31, 2024 124.33 Mn
Dec 31, 2023 144.17 Mn
Dec 31, 2022 189.20 Mn